Clinical trials
ESCC clinical trials
Below are recruiting escc clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+ - NCT07205731RecruitingPhase 2
Tislelizumab for older adults with advanced esophageal cancer
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
Annecy, Epagny Metz-TessyAges 70 years+ - NCT06637163RecruitingPhase 2
Study of benmelstobart plus chemo-radiation before surgery for esophageal cancer
This trial tests whether adding an immunotherapy drug (benmelstobart) to standard chemotherapy and radiation before surgery can help treat a certain type of esophageal cancer that can be surgically removed. The goal is to see if this combination is safe and works better than standard treatment alone.
Shantou, GuangdongAges 18 years+ - NCT06908382RecruitingPhase 2
Neoadjuvant QL1706 therapy for esophageal cancer before surgery
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Jinan, ShandongAges 18–75 - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT07177794RecruitingPhase 3
Toripalimab and capecitabine after chemoradiotherapy for esophageal cancer
This trial tests whether adding the immunotherapy drug toripalimab and the chemotherapy pill capecitabine after standard chemoradiotherapy can help prevent esophageal cancer from coming back. It's for people with squamous cell esophageal cancer that hasn't spread far and who have just finished chemoradiotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07182149RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Denver, ColoradoAges 18 years+ - NCT07080437Recruiting
Immunotherapy and chemoradiation for elderly esophageal cancer patients
This study looks at how safe and effective a combination of immunotherapy (a treatment that helps your immune system fight cancer) and standard chemotherapy plus radiation is for older adults (70+) with a type of esophageal cancer called squamous cell carcinoma who cannot have surgery or choose not to.
Chongqing, Chongqing MunicipalityAges 70 years+ - NCT04328948RecruitingPhase 3
Preventive radiation for early esophagus cancer after chemoradiation
This Phase 3 trial tests whether giving preventive (prophylactic) radiation reduces cancer coming back in people with early esophagus cancer after standard chemoradiation. It may help by lowering the chance that microscopic cancer spreads to nearby areas.
TokyoAges 20 years+ - NCT07038629RecruitingPhase 2
Chemo, radiation, and immunotherapy for older adults with esophageal cancer
This trial tests combining chemoradiation with the immunotherapy drug iparomlimab for adults aged 70 and older with advanced esophageal cancer. The goal is to see if adding immunotherapy after standard chemoradiation improves outcomes.
Tianjin, Tianjin MunicipalityAges 70–90 - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07016737Enrolling by invitationPhase 3
Chemotherapy and radiation for returning esophageal cancer
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
Nanjing, JiangsuAges 18 years+ - NCT06964568RecruitingPhase 3
Chemoradiation followed by immunotherapy for esophageal cancer
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
ShanghaiAges 18 years+ - NCT06912074RecruitingPhase 2
Comparing shorter vs. longer radiation after chemo-immunotherapy for esophageal cancer
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
Guangzhou, GuangdongAges 18–80 - NCT06863831Enrolling by invitation
Comparing YSQTG to placebo with standard treatment for esophageal cancer
This trial tests whether adding an herbal granule (YSQTG) to standard chemotherapy with or without immunotherapy helps patients with a specific type of advanced esophageal cancer. It focuses on people whose cancer is stage III to IVa and who have not had treatment yet.
Beijing, ChaoyangAges 18–80 - NCT06769113RecruitingPhase 2
Study of HLX43 for advanced esophageal cancer
This trial tests a new drug, HLX43, for people with advanced esophageal squamous cell carcinoma that has stopped responding to or cannot tolerate standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT06676449RecruitingPhase 3
A study on radiation-sparing treatment for advanced esophageal cancer
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06644781RecruitingPhase 3
Study of Ifinatamab Deruxtecan for advanced esophageal cancer
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06601309RecruitingPhase 2
Study of treatments before surgery for esophageal cancer
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Fuzhou, FujianAges 18–75 - NCT06452602RecruitingPhase 2
Chemo-immunotherapy before chemoradiation for esophageal cancer
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT04686682RecruitingPhase 1/Phase 2
Study drug for adults with advanced cancers or AML
This early study (Phase 1/2) tests a new medicine (JAB-8263) in adults with advanced solid tumors or recurrent/refractory AML. It aims to find a safe dose and see whether it can shrink tumors or control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for escc?
- Yes. Clin2 currently lists 71 recruiting escc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a escc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a escc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.